Meeting
2016 ASCO Annual Meeting
A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma.
Authors
Manmeet Singh Ahluwalia
Cleveland Clinic, Cleveland, OH
Manmeet Singh Ahluwalia , Lisa R. Rogers , Rekha T. Chaudhary , Herbert B. Newton , Ben K. Seon , Manoj A. Jivani , Bonne J. Adams , Ronald L. Shazer , Charles P. Theuer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01564914
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2035)
DOI
10.1200/JCO.2016.34.15_suppl.2035
Abstract #
2035
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
First Author: Masamichi Takahashi
Poster
2019 Gastrointestinal Cancers Symposium
ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
First Author: Zev A. Wainberg
Poster
2018 ASCO Annual Meeting
Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
First Author: Richard D. Kim
Poster
2018 ASCO Annual Meeting
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
First Author: Zev A. Wainberg